Clinicians should discuss alternative weight-loss medications and strategies with patients.
Metabolic Disorders
Higher doses anti-tumor necrosis factor-α (anti-TNF-α) therapy may be neceessary for obese patients with ulcerative colitis (UC), according to the findings of a recently published meta-analysis.
Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.
Want to read more?
Please login or register first to view this content.